Literature DB >> 18607918

Delayed electrical stimulation and BDNF application following induced deafness in rats.

Bing-Nan Song1, Yong-Xin Li, De-Min Han.   

Abstract

CONCLUSION: Under the condition of delayed intervention (30 days after deafening) following gentamicin+furosemide deafening in rats, we conclude that chronic intracochlear electrical stimulation (ES) and continuous intracochlear administration of brain-derived neurotrophic factor (BDNF) enhance spiral ganglion cell (SGC) body and peripheral process survival and improve auditory sensitivity. Moreover, the combination of ES and BDNF has a synergistic protective effect rather than an additive effect. Both SGC body and peripheral process influence the auditory sensitivity, and the latter appears to be more important.
OBJECTIVE: To determine the influence of delayed application of combined ES and neurotrophins on the survival of SGC body and peripheral processes after induced deafness in the rat. This study also explored the relationship between auditory sensitivity and SGC/peripheral process density.
MATERIALS AND METHODS: The left cochlea of profoundly deafened rats was implanted with an electrode and drug-delivery system 30 days after deafening. BDNF or artificial perilymph (AP) was delivered continuously for 28 days. Experimental animals received ES with or without BDNF (BDNF+ES and ES+AP), and control animals received BDNF or AP without ES (BDNF and AP). The right cochleae of the animals served as deafened untreated controls. Electrically evoked auditory brainstem responses (EABRs) were recorded immediately after surgery and every 7 days.
RESULTS: In the AP group, EABR thresholds demonstrated a systematic and rapid increase throughout the treatment period after the deafening procedure and electrode implantation. However, in the other three treatment groups, EABR thresholds showed a slow increase at the beginning and then slow decrease. The thresholds of the BDNF and ES+AP groups were significantly less than those of the AP group from day 7 to 28 and those of the BDNF+ES group were significantly less than those of other three groups from day 21 to 28, indicating that BDNF infusion and chronic ES have a synergistic effect rather than an additive effect. In terms of SGC and peripheral process density, the difference between the treated and control ears of BDNF, ES+AP, and BDNF+ES groups was clearly significant. Analysis of the SGC/peripheral process density of the left cochlea across the treatment groups demonstrated that SGC/peripheral process density of the BDNF and ES+AP groups was significantly greater than that of the AP group and the density of the BDNF+ES group was significantly greater than that of the other three groups, indicating that BDNF infusion and chronic ES have a synergistic effect rather than an additive effect. Finally, a functional formula was developed relating the last EABR threshold and SGC density and process density.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18607918     DOI: 10.1080/00016480802043949

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  8 in total

1.  Effects of brain-derived neurotrophic factor (BDNF) on the cochlear nucleus in cats deafened as neonates.

Authors:  Cherian K Kandathil; Olga Stakhovskaya; Patricia A Leake
Journal:  Hear Res       Date:  2016-10-20       Impact factor: 3.208

2.  Brain-derived neurotrophic factor modulates auditory function in the hearing cochlea.

Authors:  David J Sly; Amy J Hampson; Ricki L Minter; Leon F Heffer; Jack Li; Rodney E Millard; Leon Winata; Allen Niasari; Stephen J O'Leary
Journal:  J Assoc Res Otolaryngol       Date:  2011-11-16

3.  Brain-derived neurotrophic factor promotes cochlear spiral ganglion cell survival and function in deafened, developing cats.

Authors:  Patricia A Leake; Gary T Hradek; Alexander M Hetherington; Olga Stakhovskaya
Journal:  J Comp Neurol       Date:  2011-06-01       Impact factor: 3.215

Review 4.  Engineering therapies in the CNS: what works and what can be translated.

Authors:  Andrew J Shoffstall; Dawn M Taylor; Erin B Lavik
Journal:  Neurosci Lett       Date:  2012-02-04       Impact factor: 3.046

Review 5.  Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness.

Authors:  Igor Khalin; Renad Alyautdin; Ganna Kocherga; Muhamad Abu Bakar
Journal:  Int J Nanomedicine       Date:  2015-04-30

6.  Long-Term in vivo Release Profile of Dexamethasone-Loaded Silicone Rods Implanted Into the Cochlea of Guinea Pigs.

Authors:  Arne Liebau; Sören Schilp; Kenneth Mugridge; Ilona Schön; Michel Kather; Bernd Kammerer; Jochen Tillein; Susanne Braun; Stefan K Plontke
Journal:  Front Neurol       Date:  2020-01-22       Impact factor: 4.003

7.  Enhanced survival of spiral ganglion cells after cessation of treatment with brain-derived neurotrophic factor in deafened guinea pigs.

Authors:  Martijn J H Agterberg; Huib Versnel; Lotte M van Dijk; John C M J de Groot; Sjaak F L Klis
Journal:  J Assoc Res Otolaryngol       Date:  2009-04-14

8.  Phosphodiesterase type 4 inhibitor rolipram improves survival of spiral ganglion neurons in vitro.

Authors:  Katharina Kranz; Athanasia Warnecke; Thomas Lenarz; Martin Durisin; Verena Scheper
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.